![]() |
市场调查报告书
商品编码
1734883
2032 年乳酸菌菌株市场预测:按类型、形态、最终用户和地区进行的全球分析Lactobacillus Strains Market Forecasts to 2032 - Global Analysis By Type, Form, End User and By Geography |
根据 Stratistics MRC 的数据,预测期内全球乳酸菌菌株市场以 7.2% 的复合年增长率成长。
乳酸桿菌菌株是一种有益菌,常见于Kefir、德国酸菜和优格等发酵食品以及人体肠道。这些益生菌能够增强免疫系统,抑制有害病原体的生长,并平衡肠道菌群,对维持消化器官系统健康至关重要。包括嗜酸乳桿菌、鼠李糖乳桿菌和干酪乳桿菌在内的各种菌株都具有特殊特性,可提供各种健康益处,例如全面支持免疫功能、改善乳糖消化和减轻胃肠不适。此外,由于其在促进肠道健康和预防某些感染疾病方面的治疗潜力,它们越来越多地被用于膳食补充剂和机能性食品中。
根据美国卫生研究院(NIH)的数据,约有390万人(占成年人口的1.6%)使用益生菌作为维护健康的一部分,其中乳酸桿菌菌株是最常服用的益生菌之一。
提高消费者对肠道健康的认识
消费者越来越意识到健康的肠道菌丛对维持整体健康的重要性。科学文献、健康影响者和医学专家指出,益生菌对免疫调节和消化器官系统平衡至关重要,这进一步增强了消费者的这种意识。乳酸桿菌菌株因其在预防腹泻、增强营养吸收和减少腹胀方面的公认益处而广受欢迎。此外,这些益生菌正透过补充剂和机能性食品积极地融入人们的日常饮食中,这推动了国际市场的稳定需求。
缺乏针对特定菌株的监管和标准化
儘管许多益生菌产品声称含有乳酸桿菌菌株,但其功效、适应症和效果往往不一致。不同地区的法律规范差异很大,并非所有国家都要求对特定菌株的健康声明进行临床检验。这导致全球益生菌标准缺乏统一性,给消费者带来困惑。此外,缺乏针对特定菌株用途的鑑定和剂量指南,可能会损害消费者的信任,并限制科学先进配方的商业化。
益生菌物质的创造
药用级益生菌研发的投资正在不断增加,乳酸桿菌菌株不仅作为膳食补充剂销售,还作为辅助治疗剂销售,包括用于治疗细菌性阴道炎、发炎性肠道疾病(IBD) 和抗生素相关性腹泻。此外,处方益生菌的出现以及证实菌株特异性功效的临床研究,为希望利用乳酸桿菌菌株治疗潜力的製药和生物技术公司开闢了新的收益来源。
价格压力大,市场竞争激烈
从跨国公司到本土补充剂品牌,众多参与者的加入使得益生菌市场(包括乳酸菌菌株)竞争异常激烈。这导致了价格战,尤其是在机能性食品和营养保健品行业。当品牌在价格而非品质和创新上竞争时,商品化就会出现,这会削弱菌株特定好处的独特价值。此外,零售连锁店中的自有品牌产品进一步削弱了高端製造商的定价能力,从而降低了其长期生存能力和盈利。
新冠疫情对乳酸菌市场产生了多方面的影响。由于消费者对免疫和肠道健康的关注度显着提升,益生菌补充剂和含有乳酸菌的机能性食品的需求旺盛。疫情期间,超过43%服用补充剂的美国人增加了免疫支持产品的消费,从而提振了短期销售。然而,市场也面临供应链中断、原材料取得受限以及生产和分销延迟等挑战,尤其是对于需要冷藏的益生菌产品。此外,产品核可和临床试验也受到监管延迟的影响,这在一定程度上抑制了创新。
预计乳酸菌细分市场在预测期内将占据最大份额
预计乳酸菌细分市场将在预测期内占据最大市场占有率。这种优势可归因于其在药品、发酵乳製品和膳食补充剂中的广泛应用,因为已被证实具有增强免疫力、促进肠道健康和帮助乳糖消化等益处。嗜酸乳桿菌是研究最多的益生菌菌株之一,它通常包含在多菌株配方中,并以其稳定性和与其他有益菌的兼容性而闻名。此外,嗜酸乳桿菌强大的临床检验和适应性确保了其在成熟市场和新兴市场的益生菌市场中持续占据主导地位。
预计在预测期内,液体部分将以最高的复合年增长率成长。
预计液体益生菌市场将在预测期内实现最高成长率。这一增长主要源于对易饮用、高效益生菌补充剂日益增长的需求。由于生物利用度更高、摄取更方便,液体製剂尤其受到老年人和儿童的青睐。液体製剂也常用于动物饲料,有助于解释该市场的快速成长。此外,随着消费者偏好转向更容易取得、功效更强的益生菌产品,液体市场预计将大幅成长。
预计亚太地区将在预测期内占据最大的市场占有率。这一领先地位的形成得益于许多因素,包括丰富的发酵食品文化遗产、日益增强的健康意识以及中国和印度等国人口的快速增长。富含益生菌的食品(如Kefir、泡菜和优格)日益普及,以及人们对其有益肠道健康的认识不断提高,显着增加了对乳酸菌产品的需求。此外,亚太地区是市场扩张的主要驱动力,该地区的本地生产商正在利用这一趋势,推出尖端的益生菌配方。
预计北美地区在预测期内将出现最高的复合年增长率,这得益于注重健康的消费者数量增加以及人们对免疫和肠道健康益处的认识不断加深。机能性食品的需求显着增长,尤其是在千禧世代和老年人群体中,他们寻求预防性保健,这推动了这一增长。此外,该地区强大的医疗保健体系和良好的法规环境也进一步支持了乳酸菌菌株市场的成长。
According to Stratistics MRC, the Global Lactobacillus Strains Market is growing at a CAGR of 7.2% during the forecast period. Lactobacillus strains are a type of good bacteria that are frequently found in fermented foods like kefir, sauerkraut, and yogurt as well as in the human gut. By strengthening the immune system, preventing the growth of dangerous pathogens, and balancing the gut microbiota, these probiotic microbes are essential for preserving digestive health. Different strains, including Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus casei, have special qualities that support immune function overall, improve lactose digestion, and lessen gastrointestinal discomfort, among other health benefits. Moreover, their therapeutic potential in promoting gut health and preventing certain infections has led to an increasing exploration of their use in dietary supplements and functional foods.
According to data from the National Institutes of Health (NIH), probiotics are indeed used by approximately 3.9 million U.S. adults, which account for 1.6% of the adult population, as part of their wellness routines. Lactobacillus strains are among the most commonly consumed probiotics.
Growing awareness of gut health among consumers
The significance of a healthy gut microbiota in preserving general wellness is becoming more widely acknowledged by consumers. Scientific publications, health influencers, and medical professionals who advocate probiotics as crucial for immune modulation and digestive balance are driving this awareness. The well-established advantages of Lactobacillus strains, in particular, like preventing diarrhea, promoting nutrient absorption, and lessening bloating, have made them popular. Moreover, these probiotics are therefore being actively added to people's daily diets through supplements and functional foods, which is driving steady demand in international markets.
Absence of strain-specific regulation and standardization
Despite the fact that many probiotic products make the claim to contain Lactobacillus strains, labeling, potency, and efficacy are frequently inconsistent. There are significant regional differences in regulatory frameworks, and not all nations require clinical validation for health claims pertaining to particular strains. This prevents probiotic standards from being harmonized globally and causes consumers to become confused. Furthermore, if strain-specific applications lack required identification and dosage guidelines, consumer confidence may be damaged, and the commercialization of scientifically advanced formulations may be restricted.
Creation of probiotic substances
Investment in the creation of pharmaceutical-grade probiotics is rising, and Lactobacillus strains are being marketed as supplements to medical treatments as well as dietary supplements. Treatments for bacterial vaginosis, inflammatory bowel disease (IBD), antibiotic-associated diarrhea, and other conditions are among them. Moreover, the emergence of prescription probiotics and clinical studies confirming strain-specific effects opens up new revenue streams for pharmaceutical and biotech companies hoping to leverage Lactobacillus strains' therapeutic potential.
High levels of price pressure and market competition
The introduction of many players, from global firms to local supplement brands, has made the probiotic market-which includes Lactobacillus strains-extremely competitive. There are now price wars as a result, especially in the functional food and dietary supplement industries. The distinctive value of strain-specific benefits may be diminished as a result of commoditization, which occurs when brands compete on price rather than quality or innovation. Furthermore, private-label goods in retail chains further weaken premium manufacturers' pricing power, reducing their long-term viability and profitability.
The COVID-19 pandemic affected the market for Lactobacillus strains in a variety of ways. Probiotic supplements and functional foods that contain Lactobacillus strains are in high demand as a result of the substantial increase in consumer awareness of immunity and gut health. During the pandemic, more than 43 percent of Americans who take supplements increased their consumption of immune-supporting products, which increased short-term sales. But the market also had to contend with issues like disruptions in the supply chain, restricted access to raw materials, and production and distribution delays, especially for probiotic products that were refrigerated. Additionally, product approvals and clinical trials were impacted by regulatory slowdowns, which somewhat inhibited innovation.
The lactobacillus acidophilus segment is expected to be the largest during the forecast period
The lactobacillus acidophilus segment is expected to account for the largest market share during the forecast period. This dominance is ascribed to its extensive use in pharmaceuticals, fermented dairy products, and dietary supplements because of its proven advantages in enhancing immunity, promoting gut health, and facilitating lactose digestion. One of the most studied probiotic strains is Lactobacillus acidophilus, which is frequently found in multistrain formulations and is known for its stability and compatibility with other good bacteria. Moreover, Lactobacillus acidophilus's strong clinical validation and adaptability guarantee its sustained dominance in both established and developing probiotic markets.
The liquid segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the liquid segment is predicted to witness the highest growth rate. This expansion is mostly due to the growing need for easy-to-take and efficient probiotic supplements. Due to their improved bioavailability and ease of consumption, liquid formulations are especially well-liked by older adults and children. The liquid form is also frequently used in animal feed, which helps explain its quick market growth. Additionally, the liquid market is expected to grow significantly as consumer preferences change toward more readily available and powerful probiotic options, which will be in line with larger trends in health and wellness.
During the forecast period, the Asia Pacific region is expected to hold the largest market share. Numerous factors, such as a rich cultural legacy of fermented foods, increased health consciousness, and a rapidly expanding population in nations like China and India, are contributing to this leadership. The demand for Lactobacillus-based products has increased significantly as a result of the growing popularity of probiotic-rich foods like kefir, kimchi, and yogurt as well as growing awareness of the advantages for gut health. Furthermore, Asia Pacific is becoming a major force behind market expansion as local producers in the area are leveraging this trend by launching cutting-edge probiotic formulations.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by a rise in health-conscious consumers and growing knowledge of the advantages of immunity and gut health. The demand for functional foods has significantly increased, especially among millennials and older populations looking for preventive wellness options, which is driving this growth. Moreover, the market growth for Lactobacillus strains is further supported by the region's strong healthcare system and advantageous regulatory environment.
Key players in the market
Some of the key players in Lactobacillus Strains Market include Morinaga Milk Industry Co., Ltd., Chr. Hansen Holding A/S, Danone S.A, ADM (Archer-Daniels-Midland Company), Nestle S.A, Koninklijke DSM N.V., International Flavors & Fragrances Inc., Arla Foods Inc, Lallemand Inc., Yakult Honsha Co., Ltd., DowDuPont, Chobani LLC, Kerry Inc, Post Holdings Inc and Novozymes Inc.
In September 2024, Nestle is to build its first food factory in Saudi Arabia after signing a contract commiting to the project. The Saudi Press Agency, the country's state news agency, reported that Nestle has signed up for a 117,000 sq m plot in Jeddah's Third Industrial City.
In January 2024, French food group Danone said that it had signed an agreement to sell its premium organic dairy units in the United States to investment firm Platinum Equity. The sale of the Horizon Organic and Wallaby businesses is part of the company's portfolio review and asset rotation program the company announced in March 2022, Danone said in a statement, without disclosing the financial details of the deal.
In December 2023, Kerry Group plc announces it has entered into a definitive agreement to acquire part of the global lactase enzyme business of Chr. Hansen Holding A/S and Novozymes A/S on a carve out basis. This acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger approval process.